cancer

Final data from the AGENT study confirms topline results

GOTHENBURG, Sweden, November 25, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that analysis of the AGENT study’s final data confirmed topline results presented on August 3, 2022. Moreover, no predictive gene expressions for clinical response could be identified. Isofol is continuing its efforts to terminate the AGENT study in line with applicable ethical and regulatory requirements, complete the final study report for submission to regulatory agencies and prepare a manuscript for a scientific publication. Isofol is in parallel continuing to investigate possible future paths forward for the company.

Final data from the AGENT study confirms topline results Read More »

Redeye and Isofol are inviting to the live broadcast of pre-ASCO on May 28th

In connection to this year’s major cancer congress ASCO (American Society of Clinical Oncology (https://www.asco.org/)) in Chicago in June, Redeye brings together the seven most interesting cancer companies in the Nordic region for a discussion about the major changes in progress and how the companies position themselves in this fast growing theraputic area worth over $ 100 billion a year.

Redeye and Isofol are inviting to the live broadcast of pre-ASCO on May 28th Read More »

Isofol announces that an abstract with new research resultshas been published for this year’s ASCO congress in Chicago

Isofol Medical AB (publ) announces that a scientific abstract has been published for this year’s annual Congress of the American Society of Clinical Oncology (ASCO). The abstract presents results from a retrospective study in patients treated with 5-FU and the folate leukovorin (LV) for metastatic colorectal cancer (mCRC). The study shows a clear correlation between treatment outcomes, measured as progression-free survival (PFS) and expression levels of genes controlling folate metabolism and thus conversion of LV to the active substance, (6R)-5,10-methylenetetrahydrofolate (MTHF). Patients with high gene expression for ABCC3 have an average PFS of 10.1 months versus 6.5 months for patients with low gene expression.

Isofol announces that an abstract with new research resultshas been published for this year’s ASCO congress in Chicago Read More »

Isofol reports positive efficacy data for Modufolin® (arfolitixorin) from patients treated for metastatic colorectal cancer

Isofol Medical AB (publ), a clinical oncology company, reports efficacy data for Modufolin® (arfolitixorin) from patients treated during 16 weeks for mCRC (metastatic colorectal cancer). In this ongoing Phase I/IIa study, ISO-CC-005, Isofol has separately analyzed data from patients in the first line of treatment. The data demonstrates continuous response to treatment between week 8 and week 16. Moreover, non of the treated patients in this group had progressive disease.

Isofol reports positive efficacy data for Modufolin® (arfolitixorin) from patients treated for metastatic colorectal cancer Read More »

From the ongoing ISO-CC-005 study, Isofol reports initial indications of efficacy of Modufolin® in patients with metastatic colorectal cancer

Isofol Medical AB (publ), a clinical oncology company, announces that the initial indications of Modufolin® efficacy in the ISO-CC-005 study are encouraging and support execution of the planned pivotal efficacy study, ISO-CC-007.

From the ongoing ISO-CC-005 study, Isofol reports initial indications of efficacy of Modufolin® in patients with metastatic colorectal cancer Read More »

Scroll to Top